Not Yet RecruitingNCT07204171
Safety and how the oral MG001 medicine is processed
About this title
Read the official source — NCT07204171Medication studyAges 18–65United StatesAddiction
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- Overland ParkSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateEstimated: September 2026
- Recruitment status
- Not Yet Recruiting
- Enrollment listed in the registry
- 32
- Sponsor
- National Institute on Drug Abuse (NIDA)
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT07204171
- Official title
Show the full official title
Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral MG001
Recruitment & locations
Not yet recruitingThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Overland Park
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is National Institute on Drug Abuse (NIDA), a research institute.
Does this study involve medication?
Yes. The study involves medication, including mitragynine and Placebo.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as not yet recruiting.
